First Patient Enrolled in Novel Stem Cell Trial for Heart Failure Treatment
Washington, D.C. – MedStar Heart & Vascular Institute has enrolled its first patient to a clinical trial to determine whether cardiac stem cells reduce inflammation enough to improve heart function in patients with heart failure severe enough to require a left ventricular assist device, or LVAD. STEMVAD is a randomized, double-blinded, placebo-controlled study that will assess the effects of multiple intravenous administration of CardioCell’s proprietary mesenchymal stem cells (MSCs). It is expected to enroll 30 patients. The STEMVAD trial is the next step in MedStar Heart & Vascular Institute’s earlier research that discovered “one of the major problems in heart…
